Eliem Therapeutics/ELYM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Eliem Therapeutics

Eliem Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy, with Sage Therapeutics receiving approval from the United States. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS). It has designed several lead series based on novel chemistry and selected a lead clinical candidate, ETX-123. The ETX-123 molecule displays potent activation of Kv7.2/3 in vitro with an approximately 0.7 nM EC50.

Ticker

ELYM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Wilmington, United States

Employees

9

ELYM Metrics

BasicAdvanced
$224M
Market cap
-
P/E ratio
-$0.53
EPS
-
Beta
-
Dividend rate
$224M
$11.55
$2.34
19
37.025
-12.55%
-13.01%
-13.00%
2.009
2.108
74.02%

ELYM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$1.6M
-55.56%
Profit margin
0.00%
NaN%

ELYM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 20.00%
QuarterlyAnnual
Q2 22
Actual
-$0.56
Expected
-$0.47
Surprise
20.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Eliem Therapeutics stock?

Eliem Therapeutics (ELYM) has a market cap of $224M as of June 22, 2024.

What is the P/E ratio for Eliem Therapeutics stock?

The price to earnings (P/E) ratio for Eliem Therapeutics (ELYM) stock is 0 as of June 22, 2024.

Does Eliem Therapeutics stock pay dividends?

No, Eliem Therapeutics (ELYM) stock does not pay dividends to its shareholders as of June 22, 2024.

When is the next Eliem Therapeutics dividend payment date?

Eliem Therapeutics (ELYM) stock does not pay dividends to its shareholders.

What is the beta indicator for Eliem Therapeutics?

Eliem Therapeutics (ELYM) does not currently have a Beta indicator.

What is the Eliem Therapeutics stock price target?

The target price for Eliem Therapeutics (ELYM) stock is $, which is NaN% below the current price of $. This is an average based on projections from analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Eliem Therapeutics stock

Buy or sell Eliem Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing